Geptop has performed effectively in the identification of prokaryotic essential genes since its first release in 2013. It estimates gene essentiality for prokaryotes based on orthology and phylogeny. Genome-scale essentiality data of more prokaryotic species are available, and the information has been collected into public essential gene repositories such as DEG and OGEE. A faster and more accurate toolkit is needed to meet the increasing prokaryotic genome data. We updated Geptop by supplementing more validated essentiality data into reference set (from 19 to 37 species), and introducing multi-process technology to accelerate the computing speed. Compared with Geptop 1.0 and other gene essentiality prediction models, Geptop 2.0 can generate more stable predictions and finish the computation in a shorter time. The software is available both as an online server and a downloadable standalone application. We hope that the improved Geptop 2.0 will facilitate researches in gene essentiality and the development of novel antibacterial drugs. The gene essentiality prediction tool is available at http://cefg.uestc.cn/geptop .

No abstract

No abstract

Anti-CRISPR proteins (Acrs) can suppress the activity of CRISPR-Cas systems. Some viruses depend on Acrs to expand their genetic materials into the host genome which can promote species diversity. Therefore, the identification and determination of Acrs are of vital importance. In this work we developed a random forest tree-based tool, AcrDetector, to identify Acrs in the whole genomescale using merely six features. AcrDetector can achieve a mean accuracy of 99.65%, a mean recall of 75.84%, a mean precision of 99.24% and a mean F1 score of 85.97%; in multi-round, 5-fold crossvalidation (30 different random states). To demonstrate that AcrDetector can identify real Acrs precisely at the whole genome-scale we performed a cross-species validation which resulted in 71.43% of real Acrs being ranked in the top 10. We applied AcrDetector to detect Acrs in the latest data. It can accurately identify 3 Acrs, which have previously been verified experimentally. A standalone version of AcrDetector is available at https://github.com/RiversDong/AcrDetector. Additionally, our result showed that most of the Acrs are transferred into their host genomes in a recent stage rather than early.

Alzheimer’s disease (AD) is a neurodegenerative disease that eventually affects memory and behavior. The identification of biomarkers based on risk factors for AD provides insight into the disease since the exact cause of AD remains unknown. Several studies have proposed microRNAs (miRNAs) in blood as potential biomarkers for AD. Exposure to heavy metals is a potential risk factor for onset and development of AD. Blood cells of subjects that are exposed to lead detected in the circulatory system, potentially reflect molecular responses to this exposure that are similar to the response of neurons. In this study we analyzed blood cell-derived miRNAs derived from a general population as proxies of potentially AD-related mechanisms triggered by lead exposure. Subsequently, we analyzed these mechanisms in the brain tissue of AD subjects and controls. A total of four miRNAs were identified as lead exposure-associated with hsa-miR-3651, hsa-miR-150-5p and hsa-miR-664b-3p being negatively and hsa-miR-627 positively associated. In human brain derived from AD and AD control subjects all four miRNAs were detected. Moreover, two miRNAs (miR-3651, miR-664b-3p) showed significant differential expression in AD brains versus controls, in accordance with the change direction of lead exposure. The miRNAs’ gene targets were validated for expression in the human brain and were found enriched in AD-relevant pathways such as axon guidance. Moreover, we identified several AD relevant transcription factors such as CREB1 associated with the identified miRNAs. These findings suggest that the identified miRNAs are involved in the development of AD and might be useful in the development of new, less invasive biomarkers for monitoring of novel therapies or of processes involved in AD development.